contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-health-market-opening-will-soon-be-tested

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Some forum detective could do some digging to figure out the buyer. It’s a pretty hefty ownership stake if it is indeed going to a single entity.

There wasn’t really much revenue to speak of. Mostly just hiring new people and investing in sales activities. Some smaller research projects, if I recall correctly.

Could you briefly tell me what he said? Has there been any revenue? What does the outlook look like?

Yes, Suna most recently spoke about Japan in Nightingale’s own webcast.

Has the Japanese market been mentioned anywhere? They’ve been there for quite a long time already. If things don’t start working in Japan, why would they work anywhere else?

The IT strategy consultant was spouting jargon again. After watching the Boston Heart webinar last May, I noted that Jeffrey Barrett was the first company representative who was able to explain the clinical significance of the test results. But now he is leaving (or has he already left?) the company. The IT strategy consultant, with their pipelines, is returning to the kind of waffle that hasn’t convinced customers. It’s frustrating that I didn’t exit my “risk-free” remaining position already in 2024.

Am I interpreting correctly that yesterday’s volume on the OTC market was 110,100 shares?                     otcmarkets.com              OTC Markets | Official site of OTCQX, OTCQB, OTCID and Pink Limited Markets

Nightingale Health

Nightingale’s growth journey has clearer guidelines thanks to revised strategy. Although the coming year will not yet be a turning point business wise for the company, the Terveystalo customer reference that is being built and new international reference that are sought still have conditions to generate evidence of successful commercial use of the company’s technology.

<p>Nightingale’s growth journey has clearer guidelines thanks to revised strategy. Although the coming year will not yet be a turning point business wise for the company, the Terveystalo customer reference that is being built and new international reference that are sought still have conditions to generate evidence of successful commercial use of the company’s technology. The visibility of success still remains weak and we stay on the sidelines waiting for the risk/return ratio to strengthen.</p> 

	2023	24e	25e
Revenue	4.2	5.0	8.5
growth-%	80.8 %	19.6 %	69.0 %
EBIT (adj.)	-18.5	-20.0	-18.7
EBIT-% (adj.)	-442.9 %	-399.7 %	-220.8 %
EPS (adj.)	-0.30	-0.32	-0.29
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	0.8	neg.	neg.

Nightingale Health: Market opening will soon be tested

Login required

Key Estimate Figures29.09.2023

Forum discussions